The National Standing Committee deploys centralized procurement to expand area and capacity!

On the evening of January 10, the national government website published the news that "Li Keqiang presided over the State Council executive meeting to deploy to accelerate the promotion of the "14th Five-Year Plan" <Outline> and the major projects identified in the special plan to expand effective investment, etc.
" The article pointed out that in the organization of the meeting At the executive meeting of the State Council of 2019, the meeting discussed and decided: to carry out the centralized procurement of medicines and high-value medical consumables in a normalized and institutionalized manner to further reduce the medical burden on patients
.
In fact, since the General Office of the State Council issued the "Opinions on Promoting the Normalization and Institutionalization of the Centralized Procurement of Medicines with Volume" on January 28 last year, the State Council has once again made a major deployment for the procurement of drugs with volume
.
The market generally believes that, according to the decision and deployment of the regular meeting of the National Assembly, the national centralized procurement work will be upgraded again in 2022, not only the number of centralized procurement will increase, but also the category of centralized procurement will be expanded again
.
Centralized procurement of more than 350 chronic disease drugs and high-value consumables, focusing on people's health, and the core goal of the state's centralized procurement with volume, aims to promote the high-quality development of domestic drugs, and further improve the accessibility and improve the Healthcare burden benefits the public
.
Today, in the process of centralized procurement, with the continuous improvement of policy supervision, more systematic and refined, the centralized procurement of national drugs and consumables/devices has gradually entered the stage of normalization and institutionalization
.
From the "4+7" pilot 11 cities to collect medicines, to the national level, there are more and more varieties of domestic medicines, and the prices are more and more rationalized
.
The data shows that the first five batches of drugs were purchased in a centralized manner, covering more than 200 varieties, with an average drop of more than 50%, and the burden of medication on patients was significantly reduced
.
Following the pace of 2021, in 2022, the centralized procurement with volume will continue to advance to the deep water area
.
This meeting of the National Standing Committee pointed out that in recent years, the reform of centralized procurement of drugs and high-value medical consumables has continued to advance, and the market-oriented mechanism has effectively suppressed the artificially high medical prices.
At the same time, it also promotes pharmaceutical companies to devote more energy to product development and quality improvement..
In accordance with the latest requirements of the State Council, in the next step, the state will promote the normalization and institutionalization of centralized and volume-based procurement, accelerate the expansion of coverage, and continue to reduce drug prices to benefit patients: First, focus on chronic diseases and common diseases, and continue to promote national-level drug collection Purchasing, all localities carry out provincial or inter-provincial alliance procurement of drugs outside the national centralized procurement
.
By the end of this year, there will be more than 350 medicines in each province at the national and provincial levels
.
The second is to gradually expand the coverage of centralized procurement of high-value medical consumables, and conduct centralized procurement at the national and provincial levels for orthopedic consumables, drug balloons, and dental implants that are of concern to the public
.
The third is to ensure the long-term stable supply of the selected drugs and consumables, strengthen supervision, and ensure that the price of the selected products does not deteriorate
.
Medical institutions should give reasonable priority to the use of the selected products
.
The fourth is to implement the policy of retaining the balance of medical insurance funds for centralized procurement, promote the reform of the salary system, reasonably increase the income of medical staff, and better mobilize their enthusiasm
.
It is not difficult to see that accelerating the centralized procurement of medicines, consumables/devices has become a new era to comprehensively promote and deepen the reform of the medical and health system, promote the "three medical linkages", better promote the solution of the public's medical problems, and promote the realization of the "three returns" goals.
core gripper
.
On September 29 last year, the General Office of the State Council issued the "14th Five-Year Plan for National Medical Security", proposing to normalize and institutionalize the implementation of the centralized procurement of drugs organized by the state and continue to expand the scope of centralized procurement of high-value medical consumables organized by the state.
, to promote centralized procurement with volume to become the dominant mode of pharmaceutical procurement in public medical institutions
.
Industry analysts pointed out that the continuous deepening of medical insurance reform has had a positive, far-reaching and lasting impact on the promotion of clinical rational drug use and the healthy development of the pharmaceutical industry
.
The clinical drug structure of medical institutions has become more scientific and reasonable, which better meets the needs of the people for clinical disease prevention and control; clinical dependence on imported drugs has been alleviated, and innovative drugs and high-quality generic drugs have an obvious encouraging effect, further boosting the development of the pharmaceutical industry Transformation and upgrading, increasing the degree of industrial agglomeration, and policy implementation has a significant effect on leading the industry
.
National procurement and provincial procurement are linked to trillion-dollar market reshuffle to accelerate.
In the past 2021, the national centralized procurement is normalized and institutionalized, and the industrial structure is being reshaped from the policy side to the market side: the fourth batch of intensively launched, the fifth batch The centralized procurement of batches and sixth batches of drugs, more and more chemicals and consumables are accelerating the squeeze out of price water; at the same time, centralized procurement accelerates the restructuring of China's pharmaceutical industry, the concentration of the generic drug industry has increased, and the proportion of innovative drugs has increased.
The trend of transformation and upgrading of the whole industry chain is obvious
.
From November 2018 to the present, China has carried out six batches of national centralized drug procurement, the scope of implementation has expanded from 11 cities to the whole country, and the procurement content has expanded from oral dosage forms to injection dosage forms, from chemical drugs to biological drugs.
The scene of “soul bargaining” with enterprises has been staged again and again: In November 2018, national organizations included the four municipalities of Beijing, Tianjin, Shanghai, and Chongqing, and the seven provincial capitals of Shenyang, Dalian, Xiamen, Guangzhou, Shenzhen, Chengdu, and Xi’an.
In the pilot program of centralized drug procurement in sub-provincial cities, the 25 selected varieties dropped by an average of 52%
.
On January 17, 2020, the second batch of centralized procurement of drugs organized by the state was opened
.
A total of 32 varieties were successfully purchased, and a total of 100 products were selected, with an average drop of 53%
.
122 companies were originally scheduled to participate, 24 were foreign-funded companies, and 77 companies were selected.
Among them, the average drop of foreign-funded original research drugs was 82%, and the average drop of generic drugs was 51%
.
On August 20, 2020, the third batch of centralized procurement of drugs organized by the state was opened, and 56 varieties were included.
Among them, 85.
5% of the products had a price drop of more than 50%, and the average drop of these products was as high as 68.
68%
.
On February 3, 2021, the fourth batch of centralized procurement of drugs organized by the state was opened
.
The procurement produced 118 selected companies, 158 selected products, and the average price of the selected products was reduced by 52%
.
On June 23, 2021, the fifth batch of state-organized centralized procurement of drugs with volume was opened
.
This procurement produced 148 selected companies, 251 selected products, and the average price of selected drugs was reduced by 56%
.
On November 26, 2021, the bidding for the sixth batch of nationally organized drugs with insulin as the procurement object was opened.
This centralized procurement covers the second- and third-generation insulins commonly used in clinical practice, including 16 generic varieties
.
The average price of the selected products is reduced by 48%, which is expected to save 9 billion yuan per year
.
The procurement of medicines and medical consumables is becoming normalized.
In addition to the procurement led by the state, the coalition procurement initiated by the local government is also in full swing
.
The data shows that as of November 2021, there are 17 alliances including 5 provincial alliances including Chongqing, 11 provincial alliances including Shaanxi, the “six provinces and two districts” alliance, and the Beijing-Tianjin-Hebei “3+N” alliance.
Covering 28 provinces, autonomous regions and municipalities directly under the Central Government (including Xinjiang Production and Construction Corps), the leading provinces include Sichuan, Guangdong, Chongqing, Heilongjiang, etc.
The provinces (autonomous regions) that have participated in the alliance most frequently are Shanxi, Hainan, Ningxia, Xinjiang and Qinghai.
The number of alliances reached 10
.
In terms of consumables, as of November 2021, there are 21 inter-provincial and cross-regional consumables procurement alliances, covering a total of 30 provinces, autonomous regions and municipalities (including Xinjiang Production and Construction Corps)
.
It is worth noting that, with clinical needs as the center, "chronic diseases and common diseases" have always been the focus of national centralized procurement
.
Among the first five batches of domestically sourced medicines, the main ones involved are systemic anti-infectives, digestive system and metabolic medicines, and cardiovascular system medicines.
These diseases are all common clinical diseases, and the top three clinical indications even occupy nearly 50% of the market share; especially the sixth batch of national centralized procurement, which fully includes second- and third-generation insulins, and the annual purchase volume reached 210 million, and a total of 42 varieties of 11 companies were finally selected
.
From the perspective of terminal demand, around the market varieties of common diseases and chronic diseases, the huge improvement in drug accessibility and affordability will further change the market pattern
.
Minet predicts that by 2029, under the influence of the "three medical linkage" series of policies, the hospital market is expected to grow to about 1,600 billion yuan at a compound growth rate of 2% to 3% per year, of which innovative drugs account for 800 billion yuan, and generic drugs account for 800 billion yuan.
Accounting for 400 billion yuan, traditional Chinese medicine and others account for 400 billion yuan, and the trend of "changing cages for birds" is obvious; in contrast, the scale of online and offline retail pharmacies in the out-of-hospital market will reach 1,150 billion yuan, and private hospitals, private clinics, and village health The scale of the hospital will reach 450 billion yuan, and the out-of-hospital market will reach the same scale as the in-hospital market
.
The seventh batch of national harvests is approaching, nearly 100 varieties meet the conditions As the sixth batch of national harvests came to an end, the seventh batch of national harvests also officially entered the public eye
.
According to data from Minet.
com, as of January 10, among the over-evaluated varieties that have not been collected, there are 98 generic drug companies that have over-evaluated 3 or more
.
According to recent industry sources, the threshold for inclusion in the seventh batch of nationally sourced drugs may be raised to 4 or more (4 over-evaluation or 3 over-evaluation + original research), then 81 generic drugs have met the conditions
.
It is worth noting that in recent years, the varieties involved in the national mass procurement can clearly find that the number of injections is increasing
.
In addition, in chronic and common diseases such as digestion, cardiovascular and endocrine, injection products also occupy a relatively large market share
.
According to the spirit of this State Council executive meeting, the fields of chronic diseases and common diseases will become the focus of centralized procurement in the next stage, which will definitely increase the market test of injection products
.
According to the data from Minet.
com, the number of over-rated injections has been increasing year by year.
Since 2021, more than 500 products (calculated by drug name + over-rated companies) have been over-rated
.
As of December 2, 2021, among the over-evaluated injections (in terms of generic names) that have not been included in the national procurement, 50 have met the competition conditions of 3 or more companies (3 over-rated or 2 over-rated + 1 original research institute).
)
.
The total sales of these 50 injections in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) will exceed 60 billion yuan in 2020, of which 22 have sales of more than 1 billion yuan.
The annual sales of piperacillin-tazobactam injection, meropenem injection and omeprazole injection exceed RMB 5 billion
.
The injections that have not been included in the national procurement and meet the conditions (source: Minet database, as of December 2, 2021) From the perspective of enterprises, among domestic pharmaceutical companies, Qilu, Kelun, Chia Tai Tianqing, Yangzijiang, Haosen, Hengrui and other companies involved a large number of varieties, and these companies have achieved good "success" in the past national procurement; among multinational companies, Pfizer, AstraZeneca, Bayer, Novartis, etc.
have many injections listed
.
Systemic antibacterial drugs are also the main focus of centralized procurement.
The second, third, and fifth batches of drugs involved in national procurement are 6, 7, and 8, respectively, and a total of 25 generic drugs have been included in the national procurement.
pick
.
According to the data of Minet.
com, as of December 22, 2021, among the antibacterial drugs for systemic use, there are 16 generic drugs that have been reviewed by 3 or more companies
.
Systemic antibacterial drugs with 3 or more over-rated companies (source: Minet database, as of December 22, 2021) Note: For sales of less than 30 million yuan, * means these 16 generic drugs in 2019 The total terminal sales of public medical institutions in China exceeded 26 billion yuan
.
Among them, 7 drugs have sales of more than 2 billion yuan, and these products with a large amount of use will likely be included in the next batch of national procurement
.
The industry generally believes that Guocai has sounded the clarion call for a comprehensive price reduction of drugs, and the dividends of medical reform have been effectively implemented to the common people
.
Only by eradicating the basis of interest from the root of drug prices can we restore the original appearance of drug prices and achieve the key point of reasonable drug prices in the true sense. .
For enterprises, purchasing with quantity is a double-edged sword.
If you grasp it, it will be a rare development opportunity for the enterprise
; Li Keqiang presided over an executive meeting of the State Council to deploy and accelerate the promotion of major projects identified in the "14th Five-Year Plan" and the "Outline" of the special plan, expand effective investment, make normal and institutionalize, and carry out centralized and volume-based procurement of drugs and high-value medical consumables to further reduce the medical burden on patients State Council Premier Li Keqiang presided over an executive meeting of the State Council on January 10, deploying and accelerating the promotion of major projects identified in the "14th Five-Year Plan" Outline and special plans, and expanding effective investment; it was decided to normalize and institutionalize the centralized development of drugs and high-value medical consumables.
Purchasing in bulk to further reduce the medical burden on patients
.
The meeting pointed out that to implement the deployment of the Party Central Committee and the State Council, all relevant departments should benchmark against the key points identified in the "14th Five-Year Plan" Outline, scientifically and effectively do a good job in the preparation of national-level special plans, further refine the goals and tasks, and propose actionable policies and specific programs
.
At present, 44 special plans have been basically prepared, and have been issued and implemented one after another
.
We must base ourselves on the current situation and focus on the long-term, and vigorously and orderly promote the implementation of the special plan for the "14th Five-Year Plan"
.
The meeting pointed out that the current economic operation is at the juncture of climbing over a hurdle
.
In accordance with the requirements of the Central Economic Work Conference, we must put stable growth in a more prominent position, firmly implement the strategy of expanding domestic demand, insist on not engaging in "flooding", and expand final consumption and effective investment in a targeted manner.
It is of great significance to ensure the smooth operation of the economy in the first quarter and the first half of the year
.
First, it is necessary to accelerate the implementation of 102 major engineering projects and special planning key projects identified in the "14th Five-Year Plan" Outline
.
Focusing on the construction of key areas such as food and energy security, advanced manufacturing and high-tech industries, infrastructure such as transportation and logistics, network communications, and urban affordable housing, establish a coordination mechanism to ensure financing, land use, and energy use. .
Relevant procedures should be simplified for projects that are included in the planning and conditions are met, especially the major water conservancy projects that have been demonstrated for many years in the early stage should be promoted as soon as possible.
have income
.
Guide the places where investment in newly started projects has declined to strengthen work and reverse the sluggish investment situation
.
Second, in accordance with the requirement that funds follow the project, the 1.
2 trillion yuan of local government special bond funds issued in the fourth quarter of last year should be allocated to specific projects as soon as possible
.
We will promptly issue the special bonds issued this year, make good use of the investment in the central budget, focus on arranging projects under construction and those that can be started as soon as possible, leverage more social investment, and strive to create more physical workload in the first quarter
.
Third, we must deepen the reform of the investment project approval system, and implement innovative measures such as the commitment system and regional assessment
.
Research and introduce policy measures to revitalize stock assets
.
The meeting pointed out that in recent years, the reform of centralized procurement of medicines and high-value medical consumables has been continuously advanced, and the market-oriented mechanism has effectively suppressed the inflated prices of medicines.
Pharmaceutical companies put more energy into product development and quality improvement
.
In the next step, it is necessary to promote the normalization and institutionalization of centralized and volume-based procurement and accelerate the expansion of coverage, and continue to reduce the price of medicines to benefit patients
.
The first is to focus on chronic diseases and common diseases, continue to promote the centralized procurement of drugs at the national level, and carry out provincial or inter-provincial alliance procurement of drugs outside the national centralized procurement
.
By the end of this year, there will be more than 350 medicines in each province at the national and provincial levels
.
The second is to gradually expand the coverage of centralized procurement of high-value medical consumables, and conduct centralized procurement at the national and provincial levels for orthopedic consumables, drug balloons, and dental implants that are of concern to the public
.
The third is to ensure the long-term stable supply of the selected drugs and consumables, strengthen supervision, and ensure that the price of the selected products does not deteriorate
.
Medical institutions should give reasonable priority to the use of the selected products
.
The fourth is to implement the policy of retaining the balance of medical insurance funds for centralized procurement, promote the reform of the salary system, reasonably increase the income of medical staff, and better mobilize their enthusiasm
.